Predictors and Outcomes in Patients With Sickle Cell Disease

Condition:   Sickle Cell Disease Intervention:   Sponsors:   St. Jude Children's Research Hospital;   Methodist Comprehensive Sickle Cell Center;   University of Memphis;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractPurpose of the ReviewTo provide a clinically useful literature review on the rheumatic manifestations of haemoglobinopathies, critically analysing the literature from the past 5  years.Recent FindingsThere are limited new data to guide the management of rheumatic manifestations of haemoglobinopathies. Data further confirm the wide spectrum of potential rheumatic/MSK involvement in haemoglobinopathies, which poses both a diagnostic and therapeutic challenge. Inflammatory arthritis may be more common than previously believed. Steroid therapy by any route of administration can provocate a potential life-threateni...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
Conclusion: Polymorphisms in the rs7557939 region of the BCL11A gene appear to somehow interfere in the clinical setting of patients with SCD, suggesting relation with the concentration of MetHb and LDH. This study pioneered an investigation into the association of hemolysis biomarkers with BCL11A gene polymorphisms in SCD.RESUMO Introdu ção: Pacientes com anemia falciforme (AF) apresentam hemólise crônica com biomarcadores séricos aumentados. Os polimorfismos genéticos do gene BLC11A modulam a hemoglobina fetal (HbF), reduzindo, assim, a hemólise. Objetivo: Associar os polim...
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial - Category: Pathology Source Type: research
Abstract Sickle cell anemia, a genetic disease caused by a mutation in the beta-globin gene, can present oral manifestations such as delayed tooth eruption and hypomineralized enamel and dentin. The aim of the present study was to evaluate the prevalence and severity of developmental defects of enamel (DDE) and delayed tooth eruption in children with sickle cell anemia. The sample comprised 56 male and female children with sickle cell anemia aged 6 to 12 years and treated at the Hematology and Hemotherapy Center of Pernambuco, Brazil. The data were collected according to the WHO criteria for DDE and tooth eruption. The pre...
Source: Brazilian Oral Research - Category: Dentistry Source Type: research
(The Mount Sinai Hospital / Mount Sinai School of Medicine) The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease (SCD) in individuals who do not have asthma.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Segments of the NHLBI Annual Sickle Cell Disease (SCD) Clinical Research Meeting are two sessions that are part of a three-day meeting that provides a yearly forum for investigators, practitioners, and interested health care providers to discuss the process of ongoing clinical trials, hear presentations about new developments in scientific and clinical aspects of SCD, and interact with other investigators and NHLBI Program Staff in an informal setting. The presentations represented in this videocast represent NHLBI staff leaders discussing progresses and directions of NHLBI funded research activities.Air date: 8/14/2018 10:00:00 AM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Conditions:   Stroke Ischemic;   Sickle Cell Disease Intervention:   Other: Questionnaire/Interview Sponsors:   Medical University of South Carolina;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diagnoses Disease Intervention:   Device: HemoTypeSC Sponsor:   Silver Lake Research Corporation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Sickle Cell Disease Interventions:   Drug: Ticagrelor;   Drug: Placebo Sponsors:   AstraZeneca;   IQVIA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Children | Heart | Hospitals | Research | Sickle Cell Anemia